CVKD — Cadrenal Therapeutics Share Price
0.000.00%
Last trade - 00:00- $31.91m
- $21.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.29 | ||
| Price to Tang. Book | 4.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -147.32% | ||
| Return on Equity | -140.78% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new phase III-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. It is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). With tecarfarin, it is advancing a solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin, a vitamin K antagonist.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 25th, 2022
- Public Since
- January 20th, 2023
- No. of Shareholders
- 20
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,940,001
- Address
- 822 A1a North, Suite 306, PONTE VEDRA, 32082
- Web
- https://www.cadrenal.com/
- Phone
- +1 9043000701
- Contact
- Robert Blum
- Auditors
- WithumSmith Brown PC
Upcoming Events for CVKD
Similar to CVKD
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Cadrenal Therapeutics share price?
As of Today at 19:45 UTC, shares in Cadrenal Therapeutics are trading at $16.45. This share price information is delayed by 15 minutes.
How has the Cadrenal Therapeutics share price performed this year?
Shares in Cadrenal Therapeutics last closed at $16.45 and the price had moved by +135.84% over the past 365 days. In terms of relative price strength the Cadrenal Therapeutics share price has outperformed the S&P500 Index by +112.66% over the past year.
What are the analyst and broker recommendations for Cadrenal Therapeutics?
The overall consensus recommendation for Cadrenal Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cadrenal Therapeutics dividend yield?
Cadrenal Therapeutics does not currently pay a dividend.
Does Cadrenal Therapeutics pay a dividend?
Cadrenal Therapeutics does not currently pay a dividend.
When does Cadrenal Therapeutics next pay dividends?
Cadrenal Therapeutics does not currently pay a dividend.
How do I buy Cadrenal Therapeutics shares?
To buy shares in Cadrenal Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cadrenal Therapeutics?
As of the previous close price of $16.45, shares in Cadrenal Therapeutics had a market capitalisation of $31.91m.
Where are Cadrenal Therapeutics shares listed?
Here are the trading details for Cadrenal Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CVKD
What kind of share is Cadrenal Therapeutics?
Based on an overall assessment of its quality, value and momentum Cadrenal Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cadrenal Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Cadrenal Therapeutics is $35.67. That is 116.84% above the last closing price of $16.45.
Analysts covering Cadrenal Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.61 for the next financial year.
Find out moreWhat is the trend in the Cadrenal Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cadrenal Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -6.11%.
As of the last closing price of $16.45, shares in Cadrenal Therapeutics were trading +15.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cadrenal Therapeutics PE Ratio?
The Cadrenal Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cadrenal Therapeutics?
We do not have data on Cadrenal Therapeutics' directors